Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma 
Welcome,         Profile    Billing    Logout  

15 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Enblo (enavogliflozin) / Daewoong Pharma, GC Biopharma, M8 Pharma
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

Recruiting
4
120
RoW
Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab.
Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes
06/26
12/26
ENRICH-PEF, NCT06350487: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction

Not yet recruiting
4
154
RoW
SGLT2 inhibitor, SGLT2 inhibitor: Enavogliflozin (Brand names: Envlo tab)
Samsung Medical Center
Heart Failure, Preserved Ejection Fraction
12/25
06/26
ARNI-TAVI, NCT05672836: ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement

Not yet recruiting
4
1040
RoW
Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy
Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD.
Aortic Valve Stenosis
12/25
04/26
NCT06141980: Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
3
134
NA
DWP16001 0.3 mg
Daewoong Pharmaceutical Co. LTD.
T2DM (Type 2 Diabetes Mellitus)
09/25
09/25
NCT05505994: The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin

Active, not recruiting
3
340
RoW
DWP16001, DWP16001 tablet, Dapagliflozin, Dapagliflozin tablet, DWP16001 Placebo, DWP16001 Placebo tablet, Dapagliflozin Placebo, Dapagliflozin Placebo tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases
02/24
09/24
ENHANCE-I, NCT05466643: A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus

Recruiting
3
240
RoW
DWP16001 0.3mg, DWP16001 Placebo
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
09/24
09/24
EVENT, NCT06027307: Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation

Recruiting
3
540
RoW
Enavogliflozin, Envlo (brand name), Placebo
Asan Medical Center, Daewoong Pharmaceutical Co. LTD.
Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction
04/26
10/27
NCT05207176: Study to Evaluate the Safety and PK Properties of DWP16001 in Healthy Subjects With Various Ethnicities

Not yet recruiting
1
24
NA
DWP16001
Daewoong Pharmaceutical Co. LTD.
Healthy
04/22
08/22
NCT05321732: The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults

Enrolling by invitation
1
24
RoW
DWP16001, DWP202010
Daewoong Pharmaceutical Co. LTD.
Healthy Volunteers
08/22
08/22
NCT05500898: Drug-Drug Interaction of DWP16001 in Combination With DWC202204 and DWC202205 in Healthy Male Adults

Not yet recruiting
1
53
NA
DWP16001, DWC202204+DWC202205, DWP16001+DWC202204+DWC202205
Daewoong Pharmaceutical Co. LTD.
Healthy
10/22
02/23
NCT05737771: To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

Recruiting
1
40
RoW
DWC202213, DWJ1563, DWP16001
Daewoong Pharmaceutical Co. LTD.
FDC, Diabetes Mellitus, Type 2
03/23
06/23
NCT05797922: To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult Volunteers

Recruiting
1
32
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Healthy
05/23
11/23
NCT05747664: To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic Function

Recruiting
1
24
RoW
DWP16001, DWP16001 0.3mg
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
04/24
04/24
NCT06427083: Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Not yet recruiting
N/A
240
NA
Envlo Tablet, Envolomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Type 2 Diabetes Mellitus
12/25
06/26
NCT05926414: To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Recruiting
N/A
15000
RoW
Enavogliflozin, Envlo Tablet, Envlomet SR Tablet
Daewoong Pharmaceutical Co. LTD.
Diabetes Mellitus, Type 2
12/24
06/25

Download Options